Funding for this research was provided by:
Gilead Sciences (XXXXX)
Received: 27 February 2020
Accepted: 22 January 2021
First Online: 30 March 2021
Ethics approval and consent to participate
: <i>Human sample collection.</i>Prior to blood collection, all individuals gave written informed consent in compliance with the Institutional Review Board-approved protocols for STEMCELL™ Technologies (Vancouver, BC) or AllCells® (Alameda, CA).<i>Animal study.</i>This basic study design and animal usage was approved by Bolder BioPATH’s Institutional Animal Care and Use Committee (IACUC) for compliance with regulations prior to study initiation (IACUC Protocol #BBP-005).
: Not applicable.
: All authors are employees of Gilead Sciences, Inc. CWP and CS hold stock in and receive research funding from the company. CS, ASC, RMJ, DAL, DWN, FGM, KSC, and JAD hold stock in the company. ZHC, BPM, and MDI declare they have no competing interests.